His primary areas of investigation include Internal medicine, Multiple myeloma, Gastroenterology, Pathology and Surgery. His Internal medicine research is multidisciplinary, incorporating elements of Immunology and Oncology. His Immunology study incorporates themes from Molecular biology and Single-nucleotide polymorphism.
His Multiple myeloma study combines topics in areas such as Monoclonal gammopathy of undetermined significance, Clinical trial, Zoledronic acid, Bone disease and Flow cytometry. His study in Gastroenterology is interdisciplinary in nature, drawing from both Chromosome 13, Aneuploidy, Melphalan, Dexamethasone and Bence Jones protein. His work deals with themes such as Leukemia and Immunophenotyping, Antigen, which intersect with Pathology.
Internal medicine, Multiple myeloma, Oncology, Immunology and Pathology are his primary areas of study. His Internal medicine study incorporates themes from Gastroenterology and Surgery. His study in Multiple myeloma is interdisciplinary in nature, drawing from both Monoclonal gammopathy of undetermined significance, Cancer research and Bone marrow, Minimal residual disease.
His research in Oncology intersects with topics in Waldenstrom macroglobulinemia, Clinical trial, Bioinformatics and Disease. His Immunology research includes elements of Molecular biology and Stem cell. He interconnects Flow cytometry and Immunophenotyping in the investigation of issues within Pathology.
Ramón García-Sanz mainly investigates Internal medicine, Oncology, Multiple myeloma, Transplantation and In patient. His study in Gastroenterology extends to Internal medicine with its themes. His research integrates issues of Pembrolizumab, Philadelphia Chromosome Positive, Phases of clinical research, Bortezomib and Hazard ratio in his study of Oncology.
His Bortezomib research is multidisciplinary, incorporating perspectives in Denosumab and Zoledronic acid. His Multiple myeloma study combines topics in areas such as Single-nucleotide polymorphism and Bone marrow, Minimal residual disease. His biological study spans a wide range of topics, including Refractory Hodgkin Lymphoma, Discontinuation and Pathogenesis.
Ramón García-Sanz focuses on Internal medicine, Oncology, Multiple myeloma, Transplantation and Minimal residual disease. He combines subjects such as Pembrolizumab, Clinical endpoint, Refractory Hodgkin Lymphoma and Treatment efficacy with his study of Oncology. His studies in Multiple myeloma integrate themes in fields like Clinical trial, Proportional hazards model, Disease, Bone disease and Bone marrow.
His Bone disease study combines topics from a wide range of disciplines, such as Surgery, Radiation therapy and Discontinuation. The Transplantation study which covers Lenalidomide that intersects with Bortezomib and Thalidomide. Ramón García-Sanz has included themes like Multiplex polymerase chain reaction, Gene rearrangement, Lymphoid neoplasms, Radiology and DNA sequencing in his Minimal residual disease study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.
J J M van Dongen;A W Langerak;M Brüggemann;P A S Evans.
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial
María-Victoria Mateos;Albert Oriol;Joaquín Martínez-López;Norma Gutiérrez.
Lancet Oncology (2010)
New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells
Ernesto Pérez-Persona;María-Belén Vidriales;Gema Mateo;Ramón García-Sanz.
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study
María-Victoria Mateos;María-Victoria Mateos;José-M. Hernández;José-M. Hernández;Miguel-T. Hernández;Miguel-T. Hernández;Norma-C. Gutiérrez;Norma-C. Gutiérrez.
Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
J Flores-Montero;L Sanoja-Flores;B Paiva;N Puig.
Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma
Joaquin Martinez-Lopez;Juan J. Lahuerta;François Pepin;Marcos González.
Primary Plasma Cell Leukemia: Clinical, Immunophenotypic, DNA Ploidy, and Cytogenetic Characteristics
R. Garcı́a-Sanz;A. Orfão;M. González;M.D. Tabernero.
International prognostic scoring system for Waldenstrom macroglobulinemia
Pierre Morel;Alain Duhamel;Paolo Gobbi;Meletios A. Dimopoulos.
International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease
Evangelos Terpos;Gareth Morgan;Meletios Athanasios Dimopoulos;Matthew T. Drake.
Journal of Clinical Oncology (2013)
A primitive hematopoietic cell is the target for the leukemic transformation in human Philadelphia-positive acute lymphoblastic leukemia
C Cobaleda;N Gutiérrez-Cianca;J Pérez-Losada;T Flores.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: